Hospira, Amgen Duel Over Biosimilar Ruling's Impact
Hospira and Amgen are crossing swords in Delaware federal court over a new Federal Circuit ruling on the obligations of biosimilars makers, debating whether it means that companies can enforce a...To view the full article, register now.
Already a subscriber? Click here to view full article